DRUG METABOLISM AND DISPOSITION
Scope & Guideline
Innovating Insights in Drug Disposition
Introduction
Aims and Scopes
- Pharmacokinetics and Drug Disposition:
Research articles often explore the pharmacokinetics of drugs, including absorption, distribution, metabolism, and excretion (ADME). This encompasses both in vivo and in vitro studies, utilizing physiologically based pharmacokinetic modeling to predict human responses. - Drug-Metabolizing Enzymes:
A key focus is on cytochrome P450 enzymes and other drug-metabolizing enzymes, examining their roles in drug metabolism, genetic polymorphisms, and variations in enzymatic activity across different populations. - Transport Mechanisms:
The journal highlights studies on drug transporters, including their regulation, function, and impact on drug absorption and disposition, emphasizing the interplay between metabolic enzymes and transport systems. - Toxicology and Drug Safety:
Research often addresses the toxicological aspects of drug metabolism, including the identification of metabolites that may contribute to adverse drug reactions and strategies for mitigating these effects. - Clinical Relevance and Biomarkers:
The journal emphasizes the clinical implications of drug metabolism research, including the identification of biomarkers for drug efficacy and safety, and the impact of genetic and environmental factors on individual drug responses. - Innovative Methodologies:
The use of novel experimental approaches, such as high-throughput screening, advanced analytical techniques, and computational modeling, is frequently reported to enhance our understanding of drug metabolism and disposition.
Trending and Emerging
- Precision Medicine and Pharmacogenomics:
There is an increasing emphasis on precision medicine and pharmacogenomics, as studies investigate how genetic variations affect drug metabolism, efficacy, and safety, paving the way for individualized therapeutic strategies. - Physiologically Based Pharmacokinetic (PBPK) Modeling:
The use of PBPK modeling is on the rise, allowing for more accurate predictions of drug behavior in humans based on in vitro data, enhancing the relevance of preclinical studies to clinical outcomes. - Gut Microbiome Interactions:
Emerging research on the role of the gut microbiome in drug metabolism is gaining traction, highlighting how microbial metabolites can influence drug efficacy and toxicity. - Transporter Biology and Drug Disposition:
There is a growing focus on the roles of transporters in drug absorption and disposition, particularly how they interact with metabolic enzymes and their implications for drug-drug interactions. - Innovative Drug Delivery Systems:
Research into novel drug delivery systems, such as nanoparticles and liposomal formulations, is trending, reflecting a broader interest in optimizing drug bioavailability and therapeutic outcomes. - Environmental and Dietary Influences:
Recent studies are increasingly examining how environmental factors and dietary components affect drug metabolism, emphasizing the importance of lifestyle in pharmacokinetic profiles.
Declining or Waning
- Traditional In Vitro Models:
There seems to be a waning interest in conventional in vitro models for drug metabolism, such as using only liver microsomes or hepatocytes, as researchers increasingly adopt more sophisticated systems like 3D cell cultures or organ-on-chip technologies. - Non-Cytochrome P450 Enzyme Studies:
Research specifically focused on non-cytochrome P450 enzymes appears to be less frequent, suggesting a shift towards more detailed investigations of cytochrome P450 enzymes and their interactions with other metabolic pathways. - General Drug Interaction Studies:
There is a noticeable decline in the publication of generic drug-drug interaction studies without a specific focus on mechanisms, as the field moves towards more nuanced explorations of specific pathways and genetic influences. - Animal Models for Drug Metabolism:
The reliance on traditional animal models for drug metabolism studies is decreasing, with a growing emphasis on humanized models and in vitro systems that better predict human responses. - Historical Perspectives:
Papers providing broad historical overviews on drug metabolism topics are becoming less common, indicating a shift towards more focused, cutting-edge research that addresses current challenges in drug metabolism and pharmacokinetics.
Similar Journals
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Innovating Solutions for Modern Pharmaceutical ChallengesDrug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.
PHARMAZIE
Advancing pharmaceutical knowledge since 1947.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
DRUG METABOLISM REVIEWS
Advancing knowledge in pharmacology and toxicology.Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.
DARU-Journal of Pharmaceutical Sciences
Elevating the discourse in drug discovery and pharmacology.DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Unveiling New Horizons in Pharmacology and Drug DevelopmentASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.
Expert Opinion on Drug Metabolism & Toxicology
Leading the Charge in Drug Metabolism InsightsExpert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Elevating cancer research with expert reviews and methodologies.Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.
Drug Metabolism and Pharmacokinetics
Connecting Science and Practice in Pharmaceutical DevelopmentDrug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.
Ars Pharmaceutica
Pioneering research that shapes the future of pharmacy.Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.
XENOBIOTICA
Shaping the Future of Toxicology and Pharmacology.XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.